Sanofi struck its first partnership with ScionxBio to screen Sanofi’s mRNA candidates using ScionxBio’s platform for longer-acting RNA approaches. The collaboration is positioned around early discovery and candidate selection rather than late-stage clinical development. The move signals Sanofi’s continued effort to extend the durability and dosing convenience of nucleic-acid medicines, where delivery and pharmacokinetics often determine real-world usability. By tying up partner screening capabilities, Sanofi aims to compress early selection cycles for candidates that better match long-acting profiles. For the RNA ecosystem, the deal highlights how platform-focused companies are increasingly bundling discovery capacity with big-pharma pipeline expansion. It also reinforces that long-acting RNA remains a priority modality category as developers compete on dosing interval and patient convenience.